Cambodia

Population 2018 16 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>49 (27–77)</td>
<td>302 (169–473)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>1.1 (0.59–1.7)</td>
<td>6.5 (3.6–10)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>1 (0.46–1.9)</td>
<td>6.4 (2.8–11)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>3 (1.9–4.3)</td>
<td>18 (12–26)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.38 (0.21–0.6)</td>
<td>2.3 (1.3–3.7)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases 1.8% (1.2–2.8)
- Previously treated cases 8.2% (4–16)

TB case notifications, 2018
- Total new and relapse 28 620
  - % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status 94%
  - % pulmonary 65%
  - % bacteriologically confirmedººº 53%
  - % children aged 0–14 years 19%
  - % women 36%
  - % men 45%
- Total cases notified 28 757

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018 58% (37–100)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 7% (4–12)

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
  - New cases
  - Previously treated cases

Laboratory-confirmed cases* MDR/RR-TB: 128, XDR-TB: 0
- Patients started on treatment** MDR/RR-TB: 128, XDR-TB: 0
- MDR/RR-TB cases tested for resistance to second-line drugs 125

Treatment success rate and cohort size
- New and relapse cases registered in 2017 94% 34 238
- Previously treated cases, excluding relapse, registered in 2017 79% 229
- MDR/RR-TB cases started on second-line treatment in 2016 64% 101
- XDR-TB cases started on second-line treatment in 2016

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019
- National TB budget (US$ millions) 31
  - Funding source: 17% domestic, 23% international, 60% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-02-16 Data: www.who.int/tb/data